Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / COM
-
Number of holders
-
46
-
Total 13F shares, excl. options
-
4.47M
-
Shares change
-
+1.08M
-
Total reported value, excl. options
-
$8.4M
-
Value change
-
+$2.2M
-
Put/Call ratio
-
0.13
-
Number of buys
-
20
-
Number of sells
-
-14
-
Price
-
$1.88
Significant Holders of Protalix BioTherapeutics, Inc. - COM (PLX) as of Q4 2024
55 filings reported holding PLX - Protalix BioTherapeutics, Inc. - COM as of Q4 2024.
Protalix BioTherapeutics, Inc. - COM (PLX) has 46 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 4.47M shares
.
Largest 10 shareholders include RENAISSANCE TECHNOLOGIES LLC (1.12M shares), NORTHERN TRUST CORP (732K shares), MILLENNIUM MANAGEMENT LLC (388K shares), GSA CAPITAL PARTNERS LLP (306K shares), Stratos Wealth Partners, LTD. (270K shares), BlackRock, Inc. (225K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (181K shares), MORGAN STANLEY (170K shares), CITADEL ADVISORS LLC (146K shares), and JANE STREET GROUP, LLC (114K shares).
This table shows the top 46 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.